Bortezomib: The Evidence of Its Clinical Impact in Multiple Myeloma

Core Evidence - New Zealand
doi 10.2147/ce.s7452
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Informa UK Limited

Related search

Blood Distribution of Bortezomib and Its Kinetics in Multiple Myeloma Patients

Clinical Biochemistry
MedicineClinical Biochemistry
2014English

Bortezomib for the Treatment of Multiple Myeloma Patients

Health Technology Assessment
MedicineHealth Policy
2009English

Impact of Concomitant Dexamethasone Dosing Schedule on Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma

British Journal of Haematology
Hematology
2017English

Clinical Impact of Serum Soluble SLAMF7 in Multiple Myeloma

Oncotarget
Oncology
2018English

Intracellular Glutathione Determines Bortezomib Cytotoxicity in Multiple Myeloma Cells

Blood Cancer Journal
OncologyHematology
2016English

Bortezomib Induces Heme Oxygenase-1 Expression in Multiple Myeloma

Cell Cycle
MedicineDevelopmental BiologyCell BiologyMolecular Biology
2012English

Emerging Treatments for Multiple Myeloma: Beyond Immunomodulatory Drugs and Bortezomib

Seminars in Hematology
Hematology
2009English

Cutaneous Myeloma and Bortezomib

Annals of Hematology
MedicineHematology
2009English

Establishment of a Bortezomib-Resistant Chinese Human Multiple Myeloma Cell Line: MMLAL

Cancer Cell International
Cancer ResearchOncologyGenetics
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy